© 2023 MJH Life Sciences and Cancer Network. All rights reserved.
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
A panel of experts from the Moffit Cancer Center share updates in the multiple myeloma treatment landscape, highlighting recent clinical data and aspects of their own experience.
December 14th 2022
Melissa Alsina, MD, shares her excitement for an upcoming program wherein she and other key opinion leaders from the Moffit Cancer Center review updated data and optimal treatment strategies in the setting of multiple myeloma.
January 20th 2023
Experts from the Moffit Cancer Center share insight on induction therapy strategies and optimization for patients with transplant-eligible newly diagnosed multiple myeloma.
Shared insight from experts in multiple myeloma on the real-world utilization of induction therapy and transplant for patients with newly diagnosed disease.
January 25th 2023
Centering focus on a patient scenario of transplant-eligible newly diagnosed multiple myeloma, panelists consider the role of induction therapy and transplant in this setting.
Moving on to review the management of transplant-ineligible NDMM, expert panelists highlight first-line treatment options with data from the SWOG0777 and MAIA studies.
February 1st 2023
Experts from the Moffit Cancer Center work to identify frail patients with transplant-ineligible NDMM and consider how best to select first-line therapy for this population.
Shared perspectives on the role of continued therapy in patients with transplant-ineligible newly diagnosed multiple myeloma in light of clinical data and dose adjustment strategies.